Swedish Orphan Biovitrum AB (publ), known as Sobi, had 357,636,514 common shares and the same number of votes as of 30 September 2026. The increase resulted from issuing 223,677 class C shares for commitments under the long-term incentive programme for permanent employees, known as the All Employee Programme. Under a conversion clause in the articles of association, those shares were converted into common shares. Sobi held 9,631,955 common shares on the same date. The global biopharma company has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia, reported 2025 revenue of SEK 28 billion and is listed on Nasdaq Stockholm under STO: SOBI.